Clinical Policy: Maralixibat (Livmarli)

Reference Number: CP.PHAR.543
Effective Date: 09.29.21
Last Review Date: 08.26
Line of Business: Commercial, HIM/ICHRA, Medicaid Revision Log

See Important Reminder at the end of this policy for important regulatory and legal information.

Description

Maralixibat (Livmarli®) is an ileal bile acid transporter inhibitor (IBAT).

FDA Approved Indication(s)

Livmarli is indicated for the treatment of cholestatic pruritus in patients with:

- Alagille syndrome (ALGS) 3 months of age and older
- Progressive familial intrahepatic cholestasis (PFIC) 12 months of age and older

Limitation(s) of use: Livmarli is not recommended in a subgroup of PFIC type 2 with specific ABCB11 variants resulting in non-functional or complete absence of bile salt export pump (BSEP) protein.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Livmarli is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Alagille Syndrome (must meet all)**:**

1. Diagnosis of ALGS-associated pruritus confirmed by one of the following (a or b):
   a. Genetic confirmation with presence of a mutation in *JAG1* or *NOTCH2*;
   b. Clinical confirmation of both of the following (i and ii):
      i. Bile duct paucity on liver biopsy;
      ii. Criteria meeting ≥ 3 of the 5 major classic criteria (see *Appendix D*);
2. Prescribed by or in consultation with hepatologist or gastroenterologist;
3. Age ≥ 3 months and ≤ 18 years at therapy initiation;
4. Pruritus requiring at least moderate scratching (e.g., ≥ 2 on 0-4 scale, see *Appendix E*);
5. Evidence of cholestasis that is met by ≥ 1 of the following (a – e):
   a. Total serum bile acid > 3 times upper limit of normal (ULN) for age;
   b. Conjugated bilirubin > 1 mg/dL;
   c. Fat-soluble vitamin deficiency otherwise unexplainable;
   d. Gamma-glutamyl transferase > 3 times ULN for age;
   e. Intractable pruritus explainable only by liver disease;

6. Member does not have portal hypertension or history of a hepatic decompensation event;
7. Failure of ursodeoxycholic acid, unless contraindicated or clinically significant adverse effects are experienced;†
   **Prior authorization may be required for ursodeoxycholic acid*
   †For Illinois HIM requests, the step therapy requirement above does not apply as of 1/1/2026 per IL HB 5395
8. Failure of an agent used for symptomatic relief of pruritus (e.g., antihistamine, rifampin, cholestyramine), unless clinically significant adverse effects are experienced or all are contraindicated;†
   †For Illinois HIM requests, the step therapy requirement above does not apply as of 1/1/2026 per IL HB 5395
9. Livmarli is not prescribed concurrently with other IBAT inhibitors (e.g., Bylvay™);
10. Documentation of member's current body weight in kilograms (kg);
11. If request is for oral solution, request is for 9.5 mg/mL strength;
12. If request is for tablets, documentation of member's current body weight ≥ 25 kg;
13. Dose does not exceed one of the following (a or b):
    a. For oral solution, both of the following (i and ii):
       i. 380 mcg/kg per day;
       ii. 28.5 mg (3 mL) per day;
    b. For tablets, both of the following (i or ii):
       i. 30 mg per day;
       ii. 1 tablet per day.

Approval duration: 12 months

B. Progressive Familial Intrahepatic Cholestasis (must meet all)**:**

1. Diagnosis of genetically confirmed PFIC (formerly known as Byler disease or syndrome) with presence of both of the following (a and b);
   a. Has moderate to severe pruritis (e.g., ≥ 1.5 on 0 to 4 scale);
   b. Serum bile acid (sBA) levels > 3 times the upper limit of normal (ULN) for age;
2. Prescribed by or in consultation with a hepatologist or gastroenterologist;
3. Age ≥ 12 months;
4. For PFIC type 2, member does not have ABCB11 gene variants resulting in non-functional or complete absence of the BSEP protein;
5. Member does not have portal hypertension or history of a hepatic decompensation event;
6. Failure of ursodeoxycholic acid, unless contraindicated or clinically significant adverse effects are experienced;†
   **Prior authorization may be required for ursodeoxycholic acid*
   †For Illinois HIM requests, the step therapy requirement above does not apply as of 1/1/2026 per IL HB 5395
7. Failure of an agent used for symptomatic relief of pruritus (e.g., antihistamine, rifampin, cholestyramine), unless clinically significant adverse effects are experienced or all are contraindicated;†
   †For Illinois HIM requests, the step therapy requirement above does not apply as of 1/1/2026 per IL HB 5395
8. Livmarli is not prescribed concurrently with other IBAT inhibitors (e.g., Bylvay);
9. Documentation of member's current body weight in kg;

10. If request is for oral solution, request is for 19 mg/mL strength;
11. If request is for tablets, documentation of member's current body weight ≥ 25 kg;
12. Dose does not exceed one of the following (a or b):
    a. For oral solution, both of the following (i and ii):
        i. 1,140 mcg/kg per day;
        ii. 38 mg (2 mL) per day;
    b. For tablets, both of the following (i and ii):
        i. 40 mg per day;
        ii. 2 tablets per day.

Approval duration: 12 months

C. Other diagnoses/indications (must meet 1 or 2)**:**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
    a. For drugs on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, and CP.PMN.255 for Medicaid; or
    b. For drugs NOT on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid.

II. Continued Therapy

A. Alagille Syndrome (must meet all)**:**

1. Member meets one of the following (a or b):
    a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
    b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B);*
2. Member is responding positively to therapy as evidenced by an improvement in pruritus;
3. Livmarli is not prescribed concurrently with other IBAT inhibitors (e.g., Bylvay);
4. Documentation of member's current body weight in kg;
5. If request is for oral solution, request is for 9.5 mg/mL strength;
6. If request is for tablets, documentation of member's current body weight ≥ 25 kg;
7. If request is for a dose increase, new dose does not exceed one of the following (a or b):
    a. For oral solution, both of the following (i and ii):

i. 380 mcg/kg per day;
ii. 28.5 mg (3 mL) per day;
b. For tablets, both of the following (i and ii):
i. 30 mg per day;
ii. 1 tablet per day.

Approval duration: 12 months

B. Progressive Familial Intrahepatic Cholestasis (must meet all):
1. Member meets one of the following (a or b):
   a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
   b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B)*;
2. Member is responding positively to therapy as evidenced by, including but not limited to, improvement in any of the following parameters:
   a. Improvement in pruritis;
   b. Reduction of sBA from baseline;
3. Livmarli is not prescribed concurrently with other IBAT inhibitors (e.g., Bylvay);
4. Documentation of member's current body weight in kg;
5. If request is for oral solution, request is for 19 mg/mL strength;
6. If request is for tablets, documentation of member's current body weight ≥ 25 kg;
7. If request is for a dose increase, new dose does not exceed one of the following (a or b):
   a. For oral solution, both of the following (i and ii):
      i. 1,140 mcg/kg per day;
      ii. 38 mg (2 mL) per day;
   b. For tablets, both of the following (i and ii):
      i. 40 mg per day;
      ii. 2 tablets per day.

Approval duration: 12 months

C. Other diagnoses/indications (must meet 1 or 2)**:**
1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
   a. For drugs on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, and CP.PMN.255 for Medicaid; or
   b. For drugs NOT on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND

criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

ALGS: Alagille syndrome
BSEP: bile salt export pump
FDA: Food and Drug Administration
IBAT: ileal bile acid transporter
ItchRO: itch reported outcome
PFIC: progressive familial intrahepatic cholestasis
sBA: serum bile acid
ULN: upper limit of normal

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
ursodeoxycholic acid (Ursodiol®)*	10-30 mg/kg/day PO	N/A
rifampin (Rifadin®)*	10 mg/kg PO	10 mg/kg/day
cholestyramine*	4-16 g/day PO in 2 divided doses	16 g/day
antihistamine*	Varies	Varies

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.
**Off-label*

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): patients with prior or active hepatic decompensation events (e.g., variceal hemorrhage, ascites, hepatic encephalopathy)
- Boxed warning(s): none reported

Appendix D: Classic Criteria, Based on Five Body Systems, for a Diagnosis of ALGS

Classic Criteria	Description
Liver/cholestasis	Usually presenting as jaundice with conjugated hyperbilirubinaemia in the neonatal period, often with pale stools
Dysmorphic facies	Broad forehead, deep-set eyes, sometimes with upslanting palpebral fissures, prominent ears, straight nose with bulbous tip, and pointed chin giving the face a somewhat triangular appearance

Classic Criteria	Description
Heart disease	Most frequently peripheral pulmonary artery stenosis, but also pulmonary atresia, atrial septal defect, ventricular septal defect, and Tetralogy of Fallot
Axial skeleton/vertebral anomalies	Characteristic 'butterfly' vertebrae may be seen on an antero-posterior radiograph, and occasionally hemivertebrae, fusion of adjacent vertebrae, and spina bifida occulta
Eye/posterior embryotoxin	Anterior chamber defects, most commonly posterior embryotoxon, which is prominence of Schwalbe's ring at the junction of the iris and cornea

Appendix E: Itch Reported Outcome (ItchRO) Scale for Pruritus

- Used to measure patients' scratching as observed by their caregiver twice daily (once in the morning and once in the evening)
- Scratching was assessed on a 5-point scale (0-4):
  - 0: none
  - 1: mild
  - 2: moderate
  - 3: severe
  - 4: very severe

Appendix F: General Information

- Livmarli will not work on PFIC type 2 with ABCB11 variants that encode for absence of BSEP-3 since Livmarli acts on the bile acid transporter. Therefore, in patients missing the BSEP-3 transporter, Livmarli may not inhibit the bile salt export pump.
- The two strengths of Livmarli oral solution, 9.5 mg/mL and 19 mg/mL, should not be substituted for one another when treating PFIC patients.

Appendix G: Genetic Confirmation of PFIC

	PFIC 1	PFIC 2	PFIC 3	PFIC 4	PFIC 5	PFIC 6	PFIC (no #)	PFIC (no #)
Protein deficiency	FIC 1	BSEP	MDR3	TJP2	FXR	MYO5B	USP53	MRP9
Mutated gene	ATP8B1	ABCB11	ABCB4	TJP2	NR1H4	MYO5B	USP53	ABCC12

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
ALGS	Oral solution: Starting dose at 190 mcg/kg PO QD, after one week increase to 380 mcg/kg PO QD, as tolerated:	Oral solution: 380 mcg/kg/day Tablets: 30 mg/day

Oral Solution: Volume per Dose (mL) by Weight		
Patient Weight (kg)	Days 1-7 (190 mcg/kg QD)	Beginning Day 8 (380 mcg/kg QD)
	9.5 mg/mL Solution (for ALGS) Volume per Dose (mL)	
5-6	0.1	0.2

Indication	Dosing Regimen	Maximum Dose

Patient Weight (kg)	Days 1-7 (190 mcg/kg QD)	Beginning Day 8 (380 mcg/kg QD)
	9.5 mg/mL Solution (for ALGS) Volume per Dose (mL)	
7-9	0.15	0.3
10-12	0.2	0.45
13-15	0.3	0.6
16-19	0.35	0.7
20-24	0.45	0.9
25-29	0.5	1
30-34	0.6	1.25
35-39	0.7	1.5
40-49	0.9	1.75
50-59	1	2.25
60-69	1.25	2.5
70 or higher	1.5	3

Tablet:

Tablets: Dosage by Weight		
Patient Weight (kg)	Days 1-7 (190 mcg/kg QD)	Beginning Day 8 (380 mcg/kg QD)
Less than 25	Use Oral Solution	Use Oral Solution
25 to 32		10 mg
33 to 43		15 mg
44 to 65	10 mg	20 mg
66 or higher	15 mg	30 mg

<table>
<tr><th>Indication</th><th>Dosing Regimen</th><th>Maximum Dose</th></tr>
<tr><td>PFIC</td><td>Oral solution: Starting dose is 285 mcg/kg PO QD in the morning, and should be increased to 285 mcg/kg PO BID, 428 mcg/kg PO BID, and then to 570 mcg/kg PO BID, as tolerated:
<table>
<tr><th colspan="4">Oral Solution: Volume per dose (mL) by weight</th></tr>
<tr><th rowspan="2">Patient weight (kg)</th><th>285 mcg/kg (QD titrated to BID)</th><th>428 mcg/kg (BID)</th><th>570 mcg/kg (BID as tolerated)</th></tr>
<tr><th colspan="3">19 mg/mL Solution (for PFIC) Volume per Dose (mL)</th></tr>
<tr><td>5</td><td>0.1</td><td>0.1</td><td>0.15</td></tr>
<tr><td>6 to 7</td><td>0.1</td><td>0.15</td><td>0.2</td></tr>
<tr><td>8</td><td>0.1</td><td>0.2</td><td>0.25</td></tr>
<tr><td>9</td><td>0.15</td><td>0.2</td><td>0.25</td></tr>
<tr><td>10 to 12</td><td>0.15</td><td>0.25</td><td>0.3</td></tr>
<tr><td>13 to 15</td><td>0.2</td><td>0.3</td><td>0.4</td></tr>
<tr><td>16 to 19</td><td>0.25</td><td>0.4</td><td>0.5</td></tr>
<tr><td>20 to 24</td><td>0.3</td><td>0.5</td><td>0.6</td></tr>
<tr><td>25 to 29</td><td>0.4</td><td>0.6</td><td>0.8</td></tr>
<tr><td>30 to 34</td><td>0.45</td><td>0.7</td><td>0.9</td></tr>
<tr><td>35 to 39</td><td>0.6</td><td>0.8</td><td>1</td></tr>
<tr><td>40 to 49</td><td>0.6</td><td>0.9</td><td>1</td></tr>
<tr><td>50 to 59</td><td>0.8</td><td>1</td><td>1</td></tr>
<tr><td>60 or higher</td><td>0.9</td><td>1</td><td>1</td></tr>
</table>
Tablet:
<table>
<tr><th colspan="4">Tablets: Dosage by Weight</th></tr>
<tr><th>Patient weight (kg)</th><th>285 mcg/kg BID</th><th>428 mcg/kg BID</th><th>570 mcg/kg BID</th></tr>
<tr><td>Less than 25</td><td rowspan="2">Use Oral Solution</td><td rowspan="2">Use Oral Solution</td><td>Use Oral Solution</td></tr>
<tr><td>25 to 32</td><td>15 mg</td></tr>
<tr><td>33 to 43</td><td>10 mg</td><td>15 mg</td><td>20 mg</td></tr>
<tr><td>44 or higher</td><td>15 mg</td><td>20 mg</td><td>20 mg</td></tr>
</table></td><td>Oral solution: 1,140 mcg/kg/day

Tablets: 40 mg/day</td></tr>
</table>

VI. Product Availability

- Oral solution: 9.5 mg/mL (for ALGS), 19 mg/mL (for PFIC)
- Tablets: 10 mg, 15 mg, 20 mg, 30 mg

VII. References

1. Livmarli Prescribing Information. Foster City, CA: Mirum Pharmaceuticals, Inc.; April 2025. Available at: https://livmarli.com/. Accessed April 14, 2026.
2. Clinical Pharmacology [database online]. Philadelphia, PA: Elsevier; 2026. Available at: https://www.clinicalkey.com/pharmacology/. Accessed May 28, 2026.

Alagille Syndrome

3. Safety and efficacy study of LUM001 with a drug withdrawal period in participants with Alagille Syndrome (ALGS) (ICONIC). ClinicalTrials.gov Identifier: NCT02160782. Available at: https://clinicaltrials.gov/ct2/show/NCT02160782. Accessed May 28, 2026.
4. Kamath BM, Baker A, Houwen R, et al. Systematic review: the epidemiology, natural history, and burden of Alagille Syndrome. J Pediatr Gastroenterol Nutr 2018 Aug;67(2):148-156.
5. Turnpenny PD and Ellard S. Alagille syndrome: pathogenesis, diagnosis and management. Eur J Hum Genet. 2012 Mar; 20(3): 251–257.
6. Gonzales E, Hardikar W, Stormon M, et al. Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomized phase 2 study. Lancet. 2021 Oct 30; 398(10311): 1581-1592.

Progressive Familial Intrahepatic Cholestasis

7. Davit-Spraul A, Gonzales E, Baussan C, and Jacquemin E. Progressive familial intrahepatic cholestasis. Orphanet Journal of Rare Diseases. 2009; 4:1. Doi:10.1186/1750-1172-4-1.
8. Gunaydin M and Cil A. Progressive familial intrahepatic cholestasis: Diagnosis, management, and treatment. Hepatic Medicine: Evidence and Research. 2018; 10: 95-104.
9. Baker A, Kerkar N, Todorova L, Kamath BM, and Houwen RHJ. Systematic review of progressive familial intrahepatic cholestasis. Clinics and Research in Hepatology and Gastroenterology. 2019; 43: 20-36.
10. Hirschfield GM, Heathcote EJ, and Gerswhin ME. Pathogenesis of cholestatic liver disease and therapeutic approaches. Reviews in Basic and Clinical Gastroenterology and Hepatology. 2010; 139(5): 1481-1496.
11. Progressive Familial Intrahepatic Cholestasis Advocacy and Resource Network. Diagnosis and treatment. Available at: https://www.pfic.org/diagnosis-and-treatment-of-pfic/. Accessed May 28, 2026.
12. ClinicalTrials.gov. A study to evaluate the efficacy and safety of Maralixibat in subjects with progressive familial intrahepatic cholestasis (MARCH-PFIC). Available at: https://classic.clinicaltrials.gov/ct2/show/NCT03905330. Accessed May 28, 2026.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Template changes applied to other diagnoses/indications and continued therapy section.	10.05.22	
RT4: updated FDA-approved indication for pediatric extension from 1 year to 3 months of age and older.	04.05.23	
3Q 2023 annual review: added Appendix E containing ItchRO scale since criteria requires at least moderate scratching; references reviewed and updated.	04.27.23	08.23

Reviews, Revisions, and Approvals	Date	P&T Approval Date
RT4: criteria updated with newly approved indication for PFIC: modified age restriction, removed minimum body weight restriction, and updated limitation of use and contraindications per FDA labeling; references reviewed and updated.	03.27.24	
3Q 2024 annual review: for initial criteria, added exclusions for portal hypertension and history of a hepatic decompensation event for both PFIC and ALGS per competitor analysis and to align with other PFIC and ALGS criteria; references reviewed and updated.	05.13.24	08.24
RT4: for PFIC, updated criteria with pediatric extension from 5 years to 12 months of age and older, added criteria for "request is for oral solution 19 mg/mL strength", and updated maximum dosing criteria in initial and continued therapy to align with prescribing information; for ALGS initial and continued therapy, added criteria for "request is for oral solution 9.5 mg/mL strength"; added new 19 mg/mL strength oral solution; for Appendix F, added supplemental information on different strengths; updated section V to align with prescribing information dosing.	08.05.24	
3Q 2025 annual review: for ALGS initial and continued therapy and PFIC continued therapy, added exclusion for concurrent use with other IBAT inhibitors; RT4: added new tablet formulation [10 mg, 15 mg, 20 mg, 30 mg] for ALGS and PFIC; for ALGS, updated criteria from "request is for oral solution 9.5 mg/mL" to "if request is for oral solution, request is for 9.5 mg/mL strength"; for PFIC, updated criteria from "request is for oral solution 19 mg/mL" to "request is for oral solution, request is for 19 mg/mL strength"; for both indications, added criteria "if request is for tablets, documentation of member's current body weight ≥ 25 kg"; for section V, updated ALGS and PFIC sections with tablet dosage by weight; references reviewed and updated. Added step therapy bypass for IL HIM per IL HB 5395.	06.30.25	08.25
3Q 2026 annual review: no significant changes; revised initial approval durations for 6 months to 12 months; added ICHRA line of business; references reviewed and updated.	04.14.26	08.26

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical

practice current at the time that this clinical policy was approved. "Health Plan" means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:
For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2021 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed,

displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.